Dr Reddys Laboratories LTD

20-F13D13G

Schedule 13D - Activist Investments

NYSE
Key executives G.V. Prasad and K. Satish Reddy transferred significant shareholdings into family trusts for estate planning and succession, following a 1:5 stock split.

Schedule 13G - Passive Investments

NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.1% beneficial ownership stake in Dr. Reddy's Laboratories Ltd. as of March 31, 2025.